S191
Clinical - Biomarkers of clinical response
ESTRO 2026
1 Biochemistry, PGIMER, Chandigarh, India. 2 Radiotherapy, PGIMER, Chandigarh, India
large number of patients needs to be conducted for further confirmation. Moreover, the pathways by which S100A7 is upregulated in OSCC need to be explored. References: Jain, A., Kotimoole, C.N., Ghoshal, S. et al. Identification of potential salivary biomarker panels for oral squamous cell carcinoma. Sci Rep11, 3365 (2021). https://doi.org/10.1038/s41598-021-82635-0Jain A, Khan AA, Kaur R, Verma RK, Bakshi J, Chatterjee A, et al. A proteomic analysis identifies higher AHSG (Alpha- 2-HS-glycoprotein) in saliva of oropharyngeal cancer patients – A potential salivary biomarker. Oral Oncol Rep. 2024;10:100478. Keywords: oral cancer, prognostic biomarker, S100A7 Digital Poster 2991 Bayesian Response-Adaptive Trial Design for Integrating Biomarkers for Personalized Radiotherapy Pavlos Kolias 1 , Ali Ajdari 2 , Alessandro Cicchetti 3 , Robert Jeraj 4,5 , Iuliana Toma-Dasu 6,7 , Daniela Thorwarth 8 , Cihan Gani 9 , Christian Thieke 10 , Nils Henrik Nicolay 11 , Claudio Fiorino 12 , Thomas Bortfeld 2 , Maximilian Niyazi 9 1 Department of Mathematics, Aristotle University of Thessaloniki, Thessaloniki, Greece. 2 Division of Radiation Biophysics, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. 3 Data Science Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. 4 Departments of Medical Physics and Human Oncology, University of Wisconsin, Madison, USA. 5 Department of Physics, University of Ljubljana, Ljubljana, Slovakia. 6 Department of Medical Radiation Physics, Karolinska Institutet, Stockholm, Sweden. 7 Department of Physics, Stockholm University, Stockholm, Sweden. 8 Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 9 Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 10 Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. 11 Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany. 12 Medical Physics, IRCCS San Raffaele Scientific Institute, Milan, Italy Purpose/Objective: Biomarker-driven precision oncology has transformed systemic therapy, yet radiotherapy still lacks validated biomarker-based stratification strategies. Traditional frequentist clinical trials demand large patient cohorts and extended trial durations, limiting timely
Purpose/Objective: S100A7, a calcium-binding protein, belonging to S100 protein superfamily, with a role in calcium homeostasis, cell cycle progression, and differentiation, anti-microbial and immunomodulatory effects, is reported to be upregulated in different cancers. Our preliminary study, by TMT-based LC- MS/MS analysis, showed upregulation of salivary S100A7 level in Head and Neck Squamous Cell Carcinoma patients. The current study was designed to explore the biomarker potential of S100A7 in a separate cohort of OSCC patients as a pilot study. Material/Methods: We recruited 109 OSCC patients, 25 oral premalignant disease (OPMD), and 56 healthy controls after approval of Institute Ethics Committee. Sandwich ELISA (Cat# EH400RB, Invitrogen) was used to analyze S100A7 levels in saliva of OSCC and OPMD cases and healthy controls. The estimation of S100A7was done in saliva collected at the time of diagnosis, and 4-6 weeks after treatment completion. All patients underwent radical surgery followed by adjuvant post-operative radiation.IHC could be performed in biopsy tissues of 56 patients with the S100A7 antibody(Cat#MA5-29538, Invitrogen). Intensity and positivity rate (H-score) of tissue section was analyzed against the tumours’ differentiation status. Statistical analysis of results was done at GraphPad Prism version 10. S100A7 levels were correlated with various clinic-pathological parameters like risk factors, TNM staging, and differentiation status. Results: The salivary S100A7 levels were significantly higher(p< 0.0001****) inOSCC (143.5±3.05ng/mL )and the OPMD (177.5±2.53ng/mL) group compared to healthy controls (88.04±1.55ng/mL), indicating its role as a diagnostic biomarker. Salivary S100A7was compared in pre-treatment and 1st follow-up(4-6 weeks) after treatment, revealing higher(p<0.0345*)levels in patients with residual disease(RD) category compared to disease free (NED) category, suggesting role as a prognostic biomarker. H-score analysis showed significantly higher expression in well(p<0.0017**) and moderately(p<0.045*) differentiated tumours in comparison with poorly differentiated tumors, suggesting S100A7 has a role in the differentiation of tumours. Survival analysis using Kaplan-Meier test showed higher S100A7 level is significantly associated with poor disease-free survival (p<0.043*), substantiating its role as a prognostic biomarker. Conclusion: The study revealed that salivary S100A7 can be used as a diagnostic and prognostic biomarker in OSCC patients; however, a multicentric diagnostic trial with
Made with FlippingBook - Share PDF online